AKT1 and ovarian cancer: To investigate whether PRIMA-1 increases CDDP sensitivity in mutant-p53 chemoresistant ovarian cancer cells and if its action is depending on Akt down-regulation, A2780cp cells were infected with adenoviral DN-Akt (MOI = 40; LacZ as control) for 48 h, treated with PRIMA-1 (0–10 μM; 8 h), and then harvested after CDDP treatment (0–10 μM; 24 h).